• 1. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 2. An integrated system for field analysis of Cd(ii) and Pb(ii) via preconcentration using nano-TiO2/cellulose paper composite and subsequent detection with a portable X-ray fluorescence spectrometer?
  Xiaofeng Lin RSC Adv., 2016,6, 9002-9006
• 3. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 4. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789
• 5. An amino group functionalized metal–organic framework as a luminescent probe for highly selective sensing of Fe3+ ions?
  Zhonghua Xiang,Chuanqi Fang,Sanhua Leng,Dapeng Cao J. Mater. Chem. A, 2014,2, 7662-7665

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Thiazolecarboxylic acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Thiazoles Thiazolecarboxylic acids and derivatives

Methyl 4-(trifluoromethyl)-1,3-thiazole-5-carboxylate (CAS No. 1289104-53-5): A Comprehensive Overview

Methyl 4-(trifluoromethyl)-1,3-thiazole-5-carboxylate, identified by its CAS number 1289104-53-5, is a significant compound in the field of pharmaceutical chemistry and bioorganic synthesis. This compound belongs to the thiazole derivatives, a class of heterocyclic compounds that have garnered considerable attention due to their diverse biological activities and potential applications in drug development.

The structural motif of methyl 4-(trifluoromethyl)-1,3-thiazole-5-carboxylate incorporates a trifluoromethyl group at the 4-position of the thiazole ring, which is a common feature in many bioactive molecules. The trifluoromethyl group enhances the lipophilicity and metabolic stability of the compound, making it an attractive scaffold for medicinal chemists. Additionally, the carboxylate moiety at the 5-position provides a site for further functionalization, enabling the synthesis of more complex derivatives with tailored pharmacological properties.

In recent years, thiazole derivatives have been extensively studied for their antimicrobial, antiviral, anti-inflammatory, and anticancer properties. The presence of both sulfur and nitrogen atoms in the thiazole ring allows for unique electronic and steric interactions with biological targets, making these compounds versatile tools in drug discovery. Methyl 4-(trifluoromethyl)-1,3-thiazole-5-carboxylate, with its specific substitution pattern, has shown promise in several preclinical studies as a lead compound for developing novel therapeutic agents.

One of the most compelling aspects of this compound is its potential application in oncology research. Thiazole derivatives have been reported to inhibit various kinases and other enzymes involved in cancer cell proliferation and survival. The trifluoromethyl group in methyl 4-(trifluoromethyl)-1,3-thiazole-5-carboxylate further enhances its binding affinity to these targets by improving hydrophobic interactions. Recent studies have demonstrated that derivatives of this compound can selectively inhibit tumor growth in vitro and in vivo without significant toxicity to normal cells.

The synthesis of methyl 4-(trifluoromethyl)-1,3-thiazole-5-carboxylate involves multi-step organic reactions that require precise control over reaction conditions and reagent selection. The introduction of the trifluoromethyl group is typically achieved through halogen-metal exchange followed by reaction with a fluorinated electrophile. The carboxylation at the 5-position can be accomplished using various carboxylation methods, such as lithiation followed by quenching with carbon dioxide or using transition metal-catalyzed carboxylation reactions.

The pharmacokinetic properties of methyl 4-(trifluoromethyl)-1,3-thiazole-5-carboxylate have been evaluated in several preclinical models. The compound exhibits good oral bioavailability and moderate tissue distribution, suggesting its potential for systemic administration. Additionally, preliminary toxicology studies indicate that it is well-tolerated at therapeutic doses, although further investigation is needed to fully assess its safety profile.

Another area where this compound shows promise is in the treatment of infectious diseases. Thiazole derivatives have been found to possess broad-spectrum antimicrobial activity against bacteria, fungi, and viruses. The unique structural features of methyl 4-(trifluoromethyl)-1,3-thiazole-5-carboxylate contribute to its ability to disrupt essential microbial processes, making it a valuable candidate for developing new antibiotics or antiviral drugs.

Recent advances in computational chemistry have also facilitated the design and optimization of thiazole-based drug candidates like methyl 4-(trifluoromethyl)-1,3-thiazole-5-carboxylate. Molecular modeling techniques allow researchers to predict binding affinities and optimize lead structures before conducting expensive wet-lab experiments. This approach has significantly accelerated the drug discovery process and has led to the identification of several promising candidates for further development.

The industrial production of methyl 4-(trifluoromethyl)-1,3-thiazole-5-carboxylate requires careful consideration of scalability and cost-effectiveness. Process optimization strategies focus on minimizing waste generation, improving yield rates, and ensuring consistent product quality. Collaborative efforts between academic researchers and pharmaceutical companies are essential to bridge the gap between laboratory-scale synthesis and large-scale manufacturing.

In conclusion, methyl 4-(trifluoromethyl)-1,3-thiazole-5-carboxylate (CAS No. 1289104-53-5) is a versatile and promising compound with significant potential in pharmaceutical research. Its unique structural features make it an attractive scaffold for developing novel therapeutic agents targeting various diseases. Continued research efforts are needed to fully explore its pharmacological properties and translate these findings into clinical applications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)